Each quarter, ASCO’s experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in lung cancer. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials.
Articles covered in this quarter’s review include:
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39.
- Johung KL, Yeh N, Desai N, et al. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol 2015; ePub October 5.
- Kelly K, Altorki N, Eberhardt W, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015 Dec 1; 33(34):4007-4014.
- Explain the role of nivolumab in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC)
- Review the current standard of care in the adjuvant treatment of surgically resected NSCLC
- Discuss the management of brain metastases in advanced NSCLC with an emphasis on ALK-rearranged NSCLC
- Apply knowledge learned to enhance the care delivered to patients with lung cancer
Continuing Education Credit
1 Credit/Point is available for participation in this course. Certificate and credit types available include:
- AMA PRA Category 1 Credits™
- Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
- Certificate of Completion may be used to document participation, but no credit will be conferred.
- This course expires on December 16, 2018. Participants must complete all necessary course components by this date to receive credit.